Alcobra plunges on Phase III ADHD drug results

October 6, 2014 2:04 PM

1 0

Alcobra plunges on Phase III ADHD drug results

The market was not enthusiastic about the company's claims of successful trial results.

Alcobra Pharma Ltd. (Nasdaq: ADHD) has claimed positive results in a Phase III study of Metadoxine Extended Release (MDX) in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Read more

To category page

Loading...